Literature DB >> 23589173

Markers of cochlear inflammation using MRI.

Johann Le Floc'h1, Winston Tan, Ravindra S Telang, Srdjan M Vlajkovic, Alfred Nuttall, William D Rooney, Beau Pontré, Peter R Thorne.   

Abstract

PURPOSE: To quantify spatial and temporal inflammation-induced changes in vascular permeability and macrophage infiltration in guinea-pig (GP) cochlea using MRI.
MATERIALS AND METHODS: GPs were injected with lipopolysaccharide (LPS) to induce cochlear inflammation. One group was injected with a gadolinium based contrast agent (GBCA) and dynamic contrast enhanced (DCE)-MRI was performed at 4, 7, and 10 days after LPS treatment. A two-compartment pharmacokinetic model was used to determine the apparent rate constant of GBCA extravasation (K(trans) ). A second group was injected with ultrasmall superparamagnetic iron oxide particles (USPIOs) and studied at 2, 3, and 7 days after LPS treatment to detect tissue USPIO uptake and correlate with histology. For both groups, control GPs were scanned similarly.
RESULTS: The signal enhancement increased substantially and more rapidly at day 4 in LPS-treated than in control cochlea shortly following GBCA injection. K(trans) of LPS-treated cochlea was maximum on day 4 at 0.0218 ± 0.0032 min(-1) and then decreased to control level at 0.0036 ± 0.0004 min(-1) by day 10. In the second group, the relative signal intensity and T2 in cochlear perilymphatic spaces on day 2 decreased, on average, by 54% and 45%, respectively, compared with baseline and then remained under control levels by day 7. This suggests the infiltration of inflammatory cells, although unconfirmed by histology.
CONCLUSION: This provides the first measurement of cochlear vascular permeability using MRI and a quantitative evaluation of the development of cochlear inflammation. MRI holds considerable potential for the assessment of disease processes such as clinical diagnosis of conditions such as labyrinthitis.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  MRI; blood-labyrinth barrier; cochlear inflammation; lipopolysaccharide; ultrasmall superparamagnetic iron oxide; vascular permeability

Mesh:

Substances:

Year:  2013        PMID: 23589173      PMCID: PMC3935384          DOI: 10.1002/jmri.24144

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  47 in total

1.  Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange.

Authors:  C S Landis; X Li; F W Telang; J A Coderre; P L Micca; W D Rooney; L L Latour; G Vétek; I Pályka; C S Springer
Journal:  Magn Reson Med       Date:  2000-10       Impact factor: 4.668

2.  Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI.

Authors:  David L Buckley
Journal:  Magn Reson Med       Date:  2002-03       Impact factor: 4.668

3.  Estimation of gadolinium-induced T1-shortening with measurement of simple signal intensity ratio between the cochlea and brain parenchyma on 3D-FLAIR: correlation with T1 measurement by TI scout sequence.

Authors:  Shinji Naganawa; Shunichi Ishihara; Shingo Iwano; Hisashi Kawai; Michihiko Sone; Tsutomu Nakashima
Journal:  Magn Reson Med Sci       Date:  2010       Impact factor: 2.471

4.  Rapid calculation of T1 using variable flip angle gradient refocused imaging.

Authors:  E K Fram; R J Herfkens; G A Johnson; G H Glover; J P Karis; A Shimakawa; T G Perkins; N J Pelc
Journal:  Magn Reson Imaging       Date:  1987       Impact factor: 2.546

5.  Detection of apoptotic change in the lipopolysaccharide (LPS)-treated cochlea of guinea pigs.

Authors:  K Watanabe; K Jinnouchi; A Hess; O Michel; T Yagi
Journal:  Hear Res       Date:  2001-08       Impact factor: 3.208

6.  Segmental enhancement of the cochlea on contrast-enhanced MR: correlation with the frequency of hearing loss and possible sign of perilymphatic fistula and autoimmune labyrinthitis.

Authors:  A S Mark; D Fitzgerald
Journal:  AJNR Am J Neuroradiol       Date:  1993 Jul-Aug       Impact factor: 3.825

7.  Analysis of pathological events at the onset of brain damage in stroke-prone rats: a proteomics and magnetic resonance imaging approach.

Authors:  Luigi Sironi; Uliano Guerrini; Elena Tremoli; Ingrid Miller; Paolo Gelosa; Alessandro Lascialfari; Ileana Zucca; Ivano Eberini; Manfred Gemeiner; Rodolfo Paoletti; Elisabetta Gianazza
Journal:  J Neurosci Res       Date:  2004-10-01       Impact factor: 4.164

8.  Contrast enhancement of the labyrinth on MR scans in patients with sudden hearing loss and vertigo: evidence of labyrinthine disease.

Authors:  S Seltzer; A S Mark
Journal:  AJNR Am J Neuroradiol       Date:  1991 Jan-Feb       Impact factor: 3.825

9.  In vivo visualization of endolymphatic hydrops in guinea pigs: magnetic resonance imaging evaluation at 4.7 tesla.

Authors:  Jing Zou; Ilmari Pyykkö; Poul Bretlau; Tomas Klason; Börje Bjelke
Journal:  Ann Otol Rhinol Laryngol       Date:  2003-12       Impact factor: 1.547

10.  Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study.

Authors:  S Floris; E L A Blezer; G Schreibelt; E Döpp; S M A van der Pol; I L Schadee-Eestermans; K Nicolay; C D Dijkstra; H E de Vries
Journal:  Brain       Date:  2003-12-22       Impact factor: 13.501

View more
  15 in total

1.  3D fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging at different stages of otosclerosis.

Authors:  Stefano Berrettini; Francesco Lombardo; Luca Bruschini; Annalisa Ciabotti; Canapicchi Raffaello; Francesca Forli
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-09-06       Impact factor: 2.503

2.  The role of monocytes and macrophages in the dynamic permeability of the blood-perilymph barrier.

Authors:  Keiko Hirose; Song-Zhe Li
Journal:  Hear Res       Date:  2019-01-20       Impact factor: 3.208

3.  Thin and open vessel windows for intra-vital fluorescence imaging of murine cochlear blood flow.

Authors:  Xiaorui Shi; Fei Zhang; Zachary Urdang; Min Dai; Lingling Neng; Jinhui Zhang; Songlin Chen; Sripriya Ramamoorthy; Alfred L Nuttall
Journal:  Hear Res       Date:  2014-04-26       Impact factor: 3.208

4.  Gentamicin Applied to the Oval Window Suppresses Vestibular Function in Guinea Pigs.

Authors:  E B King; R K Shepherd; D J Brown; J B Fallon
Journal:  J Assoc Res Otolaryngol       Date:  2017-01-03

Review 5.  Iron-based superparamagnetic nanoparticle contrast agents for MRI of infection and inflammation.

Authors:  Alexander Neuwelt; Navneet Sidhu; Chien-An A Hu; Gary Mlady; Steven C Eberhardt; Laurel O Sillerud
Journal:  AJR Am J Roentgenol       Date:  2015-03       Impact factor: 3.959

6.  Case Report: Suppurative Labyrinthitis Induced by Chronic Suppurative Otitis Media.

Authors:  Qianwen Xiao; Yuzhong Zhang; Jingrong Lv; Jun Yang; Qing Zhang
Journal:  Front Neurol       Date:  2022-06-09       Impact factor: 4.086

7.  3D-Flair sequence at 3T in cochlear otosclerosis.

Authors:  Francesco Lombardo; Sara De Cori; Gayane Aghakhanyan; Domenico Montanaro; Daniele De Marchi; Francesca Frijia; Susanna Fortunato; Francesca Forli; Dante Chiappino; Stefano Berrettini; Raffaello Canapicchi
Journal:  Eur Radiol       Date:  2016-01-08       Impact factor: 5.315

Review 8.  Pathophysiology of the cochlear intrastrial fluid-blood barrier (review).

Authors:  Xiaorui Shi
Journal:  Hear Res       Date:  2016-01-20       Impact factor: 3.208

9.  Blood-Labyrinth Barrier Permeability in Menière Disease and Idiopathic Sudden Sensorineural Hearing Loss: Findings on Delayed Postcontrast 3D-FLAIR MRI.

Authors:  M N Pakdaman; G Ishiyama; A Ishiyama; K A Peng; H J Kim; W B Pope; A R Sepahdari
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-02       Impact factor: 3.825

10.  MRI With Gadolinium as a Measure of Blood-Labyrinth Barrier Integrity in Patients With Inner Ear Symptoms: A Scoping Review.

Authors:  Christopher I Song; Jacob M Pogson; Nicholas S Andresen; Bryan K Ward
Journal:  Front Neurol       Date:  2021-05-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.